Smith & Nephew
SNNUF (OTC)
Smith & Nephew stands out as a leading medical devices manufacturer, having recently outperformed the FTSE 100 and received a price target increase from Barclays. With a current dividend yield of 2.14%, the company offers attractive potential for income-focused investors, despite experiencing a slight dip in 5-year returns. Analysts remain optimistic, with ratings including "Outperform" from Bernstein and a "Buy" from Canaccord Genuity, highlighting its growth prospects amidst recent revenue challenges.
Pros:
- Strong performance in medical devices
- Positive analyst sentiment
Cons:
- Recent revenue shortfalls
- Market volatility risk
Smith & Nephew (SNNUF) may be an appealing investment for income-focused investors seeking exposure to the medical devices sector, particularly given its current dividend yield of 2.14% and recent positive analyst ratings. However, potential investors should consider the company's mixed long-term performance, as reflected in its 5-year return of -2.13%, and evaluate their risk tolerance in light of recent revenue challenges.